Cameron DW, Xu Y, Rode R, Cohen C, Mellors J, Farthing C, Poretz D, Markowitz M, Ho D, McMahon D, Drennan D, Hill L, Sun E, Japour A; Conference on Retroviruses and Opportunistic Infections.
7th Conf Retrovir Oppor Infect Jan 30 Feb 2 2000 Conf Retrovir Oppor Infect 7th 2000 San Franc Calif. 2000 Jan 30-Feb 2; 7: 176 (abstract no. 533).
Abbott Labs, Abbott Park, IL.
Introduction: Survival analysis can illustrate cumulative rates of serial outcomes in a simple and clinically relevant manner, which may enhance the descriptive utility of multi-year studies of antiretroviral therapies. Objective: To illustrate the long-term tolerability, safety, activity and secondary responses to RTV+SQV combination therapy using survival analysis techniques. Methods: A study of RTV+SQV in 141 patients was analyzed with follow-up to three years. Survival analysis was used to illustrate the tempo and cumulative rates of serial outcomes of clinical interest. The primary outcome was suppression of plasma HIV RNA to below 200 copies/mL. Results: Through Week 144, 120/141(85%) patients experienced primary outcome (13 of 120 were after treatment intensification). 41/120 (34%) had viral rebound after the primary outcome. 15 of 41 intensified with nucleoside analogues after a rebound and 12/15(80%) patients responded and maintained their response through 144 weeks. Treatment was discontinued in 50 of 141(35%) patients, with 20% due to adverse events. No new safety issues have been identified. While many patients elected to intensify the regimen after 48 weeks to ensure continued viral suppression, 53 of 91 (58%) of the patients on-treatment remain on R-S alone through 144 weeks. Conclusion: Survivorship analysis with serial conditional outcomes of clinical interest in this study improves our ability to estimate true rates of clinically relevant outcomes. R-S with an intensification strategy has durable activity through 3 years of follow-up.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Antiretroviral Therapy, Highly Active
- Drug Therapy, Combination
- HIV Infections
- HIV Seropositivity
- Humans
- Ritonavir
- Saquinavir
- Survival Analysis
- drug therapy
- therapy
Other ID:
UI: 102243410
From Meeting Abstracts